Navigation Links
Finesse Solutions, LLC Announces OPC Connectivity With Nova BioProfile 400
Date:3/7/2008

SANTA CLARA, Calif., March 7 /PRNewswire/ -- Finesse Solutions, LLC, a manufacturer of measurement and control solutions for life sciences process applications, and Nova Biomedical, Waltham, MA, a world leader in biotechnology process monitoring announced the first TruBio(TM) OS plug-in for OPC connectivity between TruBio(TM) OS and Nova BioProfile 400, 100 Plus, Basic 4 and Basic 2 analyzers. Both companies confirmed that a TruBio(TM) OS plug-in for OPC connectivity to the Nova Flex is currently in development.

OPC (Openness, Productivity and Collaboration) has become the de facto standard for data exchange in process control systems. It has been adopted by the majority of the control system manufacturers in the bioprocess industry and has proven to be a reliable method for sharing information across different hardware platforms.

Automatic data exchange using OPC between a lab analyzer and control system reduces errors and time delays of manual sampling, and provides automated reporting of results. It also allows the control system to adjust process parameters without a 24/7 operator presence, and, in the event of process alarm conditions, alerts off-site personnel and/or takes automatic corrective action.

This level of integration enables direct consolidation of off-line lab analyzer results into existing historical data collection, automates batch report generation, and creates a complete electronic record. Printouts of standalone analyzer results do not have to be manually attached or tracked with electronic batch reports that control systems already provide.

"Taking advantage of OPC connectivity between Nova analyzers and the Finesse bioprocess control system will improve quality and yield, while reducing operating costs. For example, programming a Nova analyzer to automatically standardize an in-situ probe, or using the resulting sample data in real-time control algorithms, will increase both process understanding and control accuracy," stated Dr. Mark Selker, CTO and co-founder of Finesse.

"By redefining the standard associated with offline data to include complete integration and the value of those data as they are applied to the bioprocess automatically, Nova and Finesse continue to provide the cutting edge technology required to bring the biotechnology industry into a new era of effectiveness and profitability. The value lies in the actions upon that information. Nova and Finesse provide the compliment to each other's technologies thereby allowing our customers real-time benefits that, until now, were impossible," says Bob Fox, Director of Sales.

About Finesse Solutions, LLC

California-based Finesse Solutions, LLC, leads the way in developing new measurement and control technologies, in order to enable the transition to single-use systems, bring new capabilities to existing bioreactor platforms, and harmonize global bio-process information transfer. Our current product family provides comprehensive measurement and control solutions for upstream processes in the biotech and pharmaceutical industries. For more information, please visit us at http://www.finesse.com.

About Nova Biomedical

Nova Biomedical is committed to continue its technology leadership with advanced products that provide better, faster diagnostic information. We continue to innovate biotechnology instruments that allow faster, more economical development of drugs and other therapeutic products.


'/>"/>
SOURCE Finesse Solutions, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Finesse Solutions Expands by Opening Sales and Service Centers
2. Finesse Introduces TruBio(TM) IOQ
3. Cascade Microtech Introduces Worlds First 45 nm-capable DC/RF Parametric Probe Card Solutions, Lowers Cost of Ownership
4. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
5. Senetek PLC Announces Appointments of Key Personnel
6. Iomai Announces Year-End 2007 Financial Results and Business Progress
7. Dragon announces new product launch; increase in annual production output capacity
8. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
9. China Yingxia International Announces Q4 and FY 2007 Estimates
10. Bristol-Myers Squibb Announces Dividend
11. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Aviva Systems Biology Corporation (ASB) which ... GenWay Biotech Incorporated, a protein solutions and applications ... for both the research and diagnostic markets. ... capabilities for both entities. GenWay,s 18 years of experience ... complement ASB,s objective to become a leading provider ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... Feb. 22, 2017  PrimeVax Immuno-Oncology, Inc. announced today ... at the Annual Biocom Global Life Science Partnering Conference.  ... 11:15 AM, at the Torrey Pines Lodge, in San ... organizers at Biocom who have chosen our company, amongst ... biotechnology companies, investors, and clinical researchers," said Mr. Chen. ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences ... treatments for neurodegenerative diseases, today announced it has issued a scientific white paper ... one of a series of commentaries from ProMIS’s scientific team offering insight into ...
Breaking Biology Technology:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
Breaking Biology News(10 mins):